Imperial College London
Alternate

Dr Peter Kelleher

Faculty of Medicine, Department of Infectious Disease

Reader in Immunology
 
 
 
//

Contact

 

+44 (0)20 3315 8251p.kelleher

 
 
//

Location

 

J.2.10Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Barnes:2023:10.1038/s41591-023-02414-4,
author = {Barnes, E and Goodyear, CS and Willicombe, M and Gaskell, C and Siebert, S and I, de Silva T and Murray, SM and Rea, D and Snowden, JA and Carroll, M and Pirrie, S and Bowden, SJ and Dunachie, SJ and Richter, A and Lim, Z and Satsangi, J and Cook, G and Pope, A and Hughes, A and Harrison, M and Lim, SH and Miller, P and Klenerman, P and Richter, AG and Mentzer, A and Deeks, A and Jamsen, A and Brown, A and Conlon, C and Dold, C and Duncan, CJA and Skelly, D and Kronsteiner, B and Abraham, P and Phillips, E and Jeffery, K and Turtle, L and Frending, L and Stafford, L and Ali, M and Rongkard, P and Payne, R and Adele, S and Travis, S and Gardiner, S and Dobson, SL and Malone, T and Bibi, S and Carroll, M and Faustini, S and Foulkes, S and Frater, J and Hall, V and Hopkins, S and Islam, J and Lambe, T and Longet, S and Moore, SC and Otter, A and Rowland-Jones, SL and Thaventhir, JED and Wootton, DG and Basu, N and Gilmour, A and Irwin, S and Meacham, G and Marjot, T and Dimitriadis, S and},
doi = {10.1038/s41591-023-02414-4},
journal = {Nature Medicine},
title = {SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease},
url = {http://dx.doi.org/10.1038/s41591-023-02414-4},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml−1). Vaccine failure rates were highest in ANCA-associated vasculitis on rituximab (21/29, 72%), hemodialysis on immunosuppressive therapy (6/30, 20%) and solid organ transplant recipients (20/81, 25% and 141/458, 31%). SARS-CoV-2-specific T cell responses were detected in 513 of 580 (88%) patients, with lower T cell magnitude or proportion in hemodialysis, allogeneic hematopoietic stem cell transplantation and liver transplant recipients (versus healthy controls). Humoral responses against Omicron (BA.1) were reduced, although cross-reactive T cell responses were sustained in all participants for whom these data were available. BNT162b2 was associated with higher antibody but lower cellular responses compared to ChAdOx1 nCoV-19 vaccination. We report 474 SARS-CoV-2 infection episodes, including 48 individuals with hospitalization or death from COVID-19. Decreased magnitude of both the serological and the T cell response was associated with severe COVID-19. Overall, we identified clinical phenotypes that may benefit from targeted COVID-19 therapeutic strategies.
AU  - Barnes,E
AU  - Goodyear,CS
AU  - Willicombe,M
AU  - Gaskell,C
AU  - Siebert,S
AU  - I,de Silva T
AU  - Murray,SM
AU  - Rea,D
AU  - Snowden,JA
AU  - Carroll,M
AU  - Pirrie,S
AU  - Bowden,SJ
AU  - Dunachie,SJ
AU  - Richter,A
AU  - Lim,Z
AU  - Satsangi,J
AU  - Cook,G
AU  - Pope,A
AU  - Hughes,A
AU  - Harrison,M
AU  - Lim,SH
AU  - Miller,P
AU  - Klenerman,P
AU  - Richter,AG
AU  - Mentzer,A
AU  - Deeks,A
AU  - Jamsen,A
AU  - Brown,A
AU  - Conlon,C
AU  - Dold,C
AU  - Duncan,CJA
AU  - Skelly,D
AU  - Kronsteiner,B
AU  - Abraham,P
AU  - Phillips,E
AU  - Jeffery,K
AU  - Turtle,L
AU  - Frending,L
AU  - Stafford,L
AU  - Ali,M
AU  - Rongkard,P
AU  - Payne,R
AU  - Adele,S
AU  - Travis,S
AU  - Gardiner,S
AU  - Dobson,SL
AU  - Malone,T
AU  - Bibi,S
AU  - Carroll,M
AU  - Faustini,S
AU  - Foulkes,S
AU  - Frater,J
AU  - Hall,V
AU  - Hopkins,S
AU  - Islam,J
AU  - Lambe,T
AU  - Longet,S
AU  - Moore,SC
AU  - Otter,A
AU  - Rowland-Jones,SL
AU  - Thaventhir,JED
AU  - Wootton,DG
AU  - Basu,N
AU  - Gilmour,A
AU  - Irwin,S
AU  - Meacham,G
AU  - Marjot,T
AU  - Dimitriadis,S
AU  - Kelleher,P
AU  - Prendecki,M
AU  - Clarke,C
AU  - Mortimer,P
AU  - McIntyre,S
AU  - Selby,R
AU  - Meardon,N
AU  - Nguyen,D
AU  - Tipton,T
AU  - Longet,S
AU  - Laidlaw,S
AU  - Orchard,K
AU  - Ireland,G
AU  - Brown,K
AU  - Amirthalingam,G
AU  - Thomas,D
AU  - Kearns,P
AU  - Kirkham,A
AU  - McInnes,IB
AU  - Beesley,R
AU  - Churchill,V
AU  - Loughton,H
AU  - Insch,E
AU  - MacDonald,E
AU  - Middleton,G
AU  - Billingham,L
AU  - Lowe,F
AU  - Magwaro,S
AU  - Al-Taei,S
AU  - Arnott,M
AU  - Bennett,L
AU  - Brock,J
AU  - Keillor,V
AU  - Melville,A
AU  - Melville,L
AU  - Miller,S
AU  - Najm,A
AU  - Paterson,C
AU  - Rodgers,L
AU  - Rutherford,M
AU  - Rundell,S
AU  - Smith,E
AU  - Stewart,L
AU  - Sunzini,F
AU  - Tong,A
AU  - Woolcock,K
AU  - Basheer,F
AU  - Crawley,C
AU  - Malladi,R
AU  - King,A
AU  - Lockey,S
AU  - Uttenthal,B
AU  - Koh,MBC
AU  - Hansford,S
AU  - Sandhar,G
AU  - Kesavan,M
AU  - Moore,C
AU  - Manousou,P
AU  - Hahn,G
AU  - Mullish,B
AU  - Atta,M
AU  - Gleeson,S
AU  - Lightstone,L
AU  - Martin,P
AU  - McAdoo,S
AU  - Thomson,T
AU  - Avenoso,D
AU  - Sanderson,R
AU  - Taylor,C
AU  - Bhandal,K
AU  - Hull,D
AU  - Trivedi,P
AU  - Filer,A
AU  - Hurst,E
AU  - Publicover,A
AU  - Scouse,K
AU  - Chalk,J
AU  - Hanke,D
AU  - Hanke,J
AU  - Healy,S
AU  - Provine,N
AU  - Thomas,S
AU  - Walker,V
AU  - Win,Z
AU  - Trown,D
AU  - Faria,P
AU  - Chackathayil,J
AU  - Hutchison,C
AU  - Richardson,D
AU  - PITCH,consortium
AU  - CONSENSUS
AU  - OCTAVE,Collaborative Group
DO  - 10.1038/s41591-023-02414-4
PY  - 2023///
SN  - 1546-170X
TI  - SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
T2  - Nature Medicine
UR  - http://dx.doi.org/10.1038/s41591-023-02414-4
UR  - https://doi.org/10.1038/s41591-023-02414-4
ER  -
Download